Erratum to: New Treatment Modalities for Hepatocellular Cancer (Current Gastroenterology Reports, 17, 19, (2015), 10.1007/s11894-015-0442-4);New Treatment Modalities for Hepatocellular Cancer

Current Gastroenterology Reports

Volumn 17, Issue 5, 2015, Pages 1-2

  Mauer, Kurt ^a   O’Kelley, Ryan ^a   Podda, Nishant ^b   Flanagan, Siobhan ^c   Gadani, Sameer ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Orthopaedic Surgery   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

Author keywords

Combination therapy; HCC; Irreversible electroporation (IRE); Microwave ablation (MWA); Radiofreqency ablation (RFA); Sorafenib; Transarterial chemoembolization with drug eluting beads (DEB TACE); Transarterial radioembolization (TARE)

Indexed keywords

ALCOHOL; ANGIOGENESIS INHIBITOR; SORAFENIB;

ADVANCED CANCER; ARTIFICIAL EMBOLISM; BLAND EMBOLIZATION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED THERAPY; CRYOTHERAPY; ELECTROPORATION; EXPERIMENTAL STUDY; HUMAN; INTERMETHOD COMPARISON; IRREVERSIBLE ELECTROPORATION; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER RESECTION; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; MEDICAL TECHNOLOGY; MICROWAVE THERAPY; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PATIENT SAFETY; PERCUTANEOUS ETHANOL INJECTION; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSARTERIAL CHEMOEMBOLIZATION WITH DRUG ELUTING BEAD; TRANSARTERIAL RADIOEMBOLIZATION; TREATMENT INDICATION; ULTRASOUND THERAPY; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMPUTER ASSISTED TOMOGRAPHY; ELECTROCHEMOTHERAPY; LIVER NEOPLASMS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; ELECTROCHEMOTHERAPY; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84928139638     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-015-0475-8     Document Type: Erratum

References (50)

1. Curado M, Cancer I, Organization W, et al. Cancer incidence in five continents. Int Agency Res Cancer. 2008.
2. El-Serag H, Mason A. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227–30.
3. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262(1):43–58. Excellent discussion of recent loco-regional therapies for HCC.
4. Llovet J, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30(6):1434–40.
5. Huo T, Lin H, Hsia C, Wu J, Lee P, Chi C, et al. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol. 2007;102(9):1920–30.
6. Lencioni R, Crocetti L. Radiofrequency ablation of liver cancer. Tech Vasc Interv Radiol. 2007;10(1):38–46.
7. Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol. 2010;33(1):11–7.
8. Peng Z, Liu F, Ye S, Xu L, Zhang Y, Liang H, et al. Radiofrequency ablation versus open hepatic resection for elderly patients (>65 years) with very early or early hepatocellular carcinoma. Cancer. 2013;119(21):3812–20.
9. Imai K, Beppu T, Chikamoto A, Okabe H, Hayashi H, Nitta H, et al. Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less. Hepatol Res. 2013;43(8):853–64. Recent recommendations regarding first line treatment of very early stage HCC.
10. Lencioni R, Cioni D, Pina C, Crocetti L. Hepatocellular carcinoma: new options for image-guided ablation. J Hepato-Biliary-Pancreat Sci. 2010;17(4):399–403.
11. Ding J, Jing X, Liu J, Wang Y, Wang F, Wang Y, et al. Complications of thermal ablation of hepatic tumours: comparison of radiofrequency and microwave ablative techniques. Clin Radiol. 2013;68(6):608–15.
12. Shen A, Zhang H, Tang C, Chen Y, Wang Y, Zhang C, et al. A systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. J Gastroenterol Hepatol. 2013;28(5):793–800.
13. Livraghi T, Goldberg S, Lazzaroni S, Meloni F, Ierace T, Solbiati L, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions 1. Radiology. 2000;214(3):761–8.
14. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Cancer. 2002;95(11):2353–60.
15. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol. 2006;16(3):661–9.
16. Helmberger T, Dogan S, Straub G, Schrader A, Jungst C, Reiser M, et al. Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion. 2007;75(2–3):104–12.
17. Lencioni R, Crocetti L, Petruzzi P, Vignali C, Bozzi E, Della Pina C, et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol. 2008;49(2):217–22.
18. Phase 3 study of ThermoDox with radiofrequency ablation (RFA) in treatment of hepatocellular carcinoma (HCC). U.S. National Library of Medicine, National Institutes of Health.
19. Qian G, Wang N, Shen Q, Sheng Y, Zhao J, Kuang M, et al. Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: experimental and clinical studies. Eur Radiol. 2012;22(9):1983–90.
20. Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, et al. Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas. J Gastroenterol Gepatology. 2009;24(2):223–7.
21. Abdelaziz A, Elbaz T, Shousha H, Mahmoud S, Ibrahim M, Abdelmaksoud A. et al. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an egyptian multidisciplinary clinic experience. Surg Endosc. 2014;1–6.
22. Scheffer H, Nielsen K, de Jong M, van Tilborg A, Vieveen J, Bouwman A, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol. 2014;25(7):997–1011.
23. Molla N, AlMenieir N, Simoneau E, Aljiffry M, Valenti D, Metrakos P, et al. The role of interventional radiology in the management of hepatocellular carcinoma. Curr Oncol. 2014;21(3):480.
24. Chok K, Cheung T, Lo R, Chu F, Tsang S, Chan A, et al. Pilot study on high-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients waitlisted for liver transplant. Liver Transpl. 2014;20(8):912–21.
25. Pacella C, Francica G, Di Lascio F, Arienti V, Antico E, Caspani B, et al. Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. J Clin Oncol. 2009;27(16):2615–21.
26. Lencioni R. “Loco-regional treatment of hepatocellular carcinoma.” Hepatology. 2010 52 Print.
27. Llovet J, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–42.
28. Song M, Chun H, Song D, Kim H, Yoo S, Park C, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57(6):1244–50.
29. Skowasch M, Schneider J, Otto G, Weinmann A, Woerns M, Dueber C, et al. Midterm follow-up after DC-BEAD-TACE of hepatocellular carcinoma (HCC). Eur J Radiol. 2012;12:3857–61.
30. Boulin M, Hillon P, Cercueil J, Bonnetain F, Dabakuyo S, Minello A, et al. Idarubicin-loaded beads for chemoembolization of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther. 2014;39(11):1301–13.
31. Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, et al. A randomized phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013;108(6):1252–9.
32. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33(3):541–51.
33. Weintraub J, Salem R. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. J Vasc Interv Radiol. 2013;24(8):1123–34.
34. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52.
35. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–64.
36. Llovet J, Real M, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9.
37. Erhardt A, Kolligs F, Dollinger M, Schott E, Wege H, Bitzer M, et al. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. Cancer Chemother Pharmacol. 2014;74(5):947–54.
38. Li X, Feng G, Zheng C, Zhuo C, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol: WJG. 2004;10(19):2878–82.
39. Wakabayashi I, Groschner K. Vascular actions of anthracycline antibiotics. Curr Med Chem. 2003;10(5):427–36.
40. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist. 2012;17(3):359–66.
41. Andreana L, Isgro G, Marelli L, Davies N, Yu D, Navalkissoor S, et al. Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: trans-arterial radio-embolisation of HCC. Cancer Treat Rev. 2012;38(6):641–9.
42. Salem R, Hunter R. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: a review. Int J Radiat Oncol Biol Phys. 2006;66(2):83–8.
43. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868–78.
44. Tsai A, Burke C, Kennedy A, Moore D, Mauro M, Dixon R, et al. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010;21(9):1377–84.
45. Gadani S, Mahvash A, Avritscher R, Chasen B, Kaseb A, Murthy R. 8: 24 AM Abstract No. 62-Yttirum-90 resin microspheres as an adjunct to sorafenib in patients with unresectable HCC: a retrospective study for evaluation of survival benefit and adverse events. J Vasc Interv Radiol. 2013;24(4):35.
46. Kulik L, Vouche M, Koppe S, Lewandowski R, Mulcahy M, Ganger D, et al. Prospective randomized pilot study of Y90+/− sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014;61(2):309–17.
47. Yang M, Fang Z, Yan Z, Luo J, Liu L, Zhang W, et al. Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial. J Cancer Res Clin Oncol. 2014;140(2):211–9.
48. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.
49. Cheng A, Kang Y, Lin D, Park J, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067–75.
50. Lencioni R, Kudo M, Ye S, Bronowicki J, Chen X, Dagher L, et al. GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib): second interim analysis. Int J Clin Pract. 2014;68(5):609–17. Excellent discussion regarding combining loco-regional therapy with sorafenib.